The safety of GSK2618960 has been preliminarily established in a Phase I clinical trial (I7R116702), targeting CD127 for autoimmune conditions, where it showed no significant adverse reactions in healthy volunteers. The gene discussed is IL7R; the disease is Autoimmunity.